The estimated Net Worth of Stewart W Strong is at least $2.58 Million dollars as of 26 July 2024. Stewart Strong owns over 4,312 units of Haemonetics stock worth over $1,318,300 and over the last 16 years Stewart sold HAE stock worth over $1,264,449.
Sign up
Stewart Strong HAE stock SEC Form 4 insiders trading
Stewart has made over 9 trades of the Haemonetics stock since 2021, according to the Form 4 filled with the SEC. Most recently Stewart sold 4,312 units of HAE stock worth $393,039 on 26 July 2024.
The largest trade Stewart's ever made was selling 8,857 units of Haemonetics stock on 28 May 2024 worth over $775,253. On average, Stewart trades about 1,007 units every 39 days since 2008. As of 26 July 2024 Stewart still owns at least 18,196 units of Haemonetics stock.
You can see the complete history of Stewart Strong stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Haemonetics
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy und Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
What does Haemonetics do?
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
What does Haemonetics's logo look like?
Complete history of Stewart Strong stock trades at Atricure Inc und Haemonetics
Haemonetics executives and stock owners
Haemonetics executives and other stock owners filed with the SEC include:
-
Christopher Simon,
President, Chief Executive Officer, Director -
William Burke,
Chief Financial Officer, Executive Vice President -
Michelle Basil,
Executive Vice President, General Counsel -
Josep Llorens,
Senior Vice President - Global Manufacturing and Supply Chain -
Jacqueline Scanlan,
Senior Vice President - Human Resources -
Richard Meelia,
Independent Chairman of the Board -
Claire Pomeroy,
Independent Director -
Charles Dockendorff,
Independent Director -
Catherine Burzik,
Independent Director -
Robert Abernathy,
Independent Director -
Ellen Zane,
Independent Director -
Mark Kroll,
Independent Director -
Olga Guyette,
Director – Investor Relations -
Michael Coyle,
Independent Director -
Anila Lingamneni,
Executive Vice President, Chief Technology Officer -
Dan Goldstein,
VP, Corporate Controller -
Susan Bartlett Foote,
Director -
Ronald G Gelbman,
Director -
Neil 122 62 507 Ryding,
EVP, Global Manufacturing -
David Fusco,
EVP, Global Human Resources -
Brian R Burns,
EVP, Global QA/RA -
Sandra Jesse,
VP & CLO -
Ronald Merriman,
Director -
Susan M Hanlon,
V.P. Corporate Controller -
Kent J Davies,
President, Global Markets -
Jonathan White,
VP Research and Development -
Byron Selman,
President, Global Markets -
Pedro P Granadillo,
Director -
Said Bolorforosh,
EVP, Chief Technology Officer -
William Granville,
VP, Manufacturing -
Thomas Lawlor,
President, Patient Division -
Brad Nutter,
President & CEO -
Yutaka Sakurada,
President, Japan & Asia -
Alicia R Lopez,
Senior VP & General Counsel -
Lawrence C Best,
Director -
Donna C E Williamson,
Director -
Warren Jr Nighan,
VP WW Q&R Affairs -
Ulrich Eckert,
President, Europe & Latin Am -
Mikael Gordon,
President, Haemonetics Europe -
Mark Beucler,
-
Anthony Pare,
-
Dave Helsel,
VP, Global Manufacturing -
Harvey G Klein,
Director -
Ryoji Sakai,
President, Japan -
Ronald A Matricaria,
Director -
Remi Corlin,
President, Asia -
Mark A Popovsky,
Vp, Corporate Medical Director -
Ronald J Ryan,
Senior VP & CFO -
Stephen Swenson,
VP & General Mgr, Global Plasm -
Peter M Allen,
President, Donor Division -
Brian Concannon,
President, Patient Division -
Kathleen Mc Daniel,
EVP Global Human Resources -
James O'shaughnessy,
-
Paul Black,
Director -
Michael I Ruxin,
VP Global Software Strategies -
Robert B Ebbeling,
Senior VP, Manufacturing -
Joseph J Forish,
VP, Human Resources -
Phillip John Brancazio,
VP, Global Manufacturing -
Michael P Kelly,
President, NA, Global Plasma -
William Roche Still,
VP Strategic Mktg, & Bus. Dev. -
Benjamin L Holmes,
Director -
Keiko Hattori,
President, Haemonetics Japan -
Jan Conneely,
VP & GM, Arryx, Inc. -
Christopher J Lindop,
VP, Finance & CFO -
Laurie A. Miller,
SVP, Human Resources -
Farris Maryanne Maunsell,
VP, Chief Accounting Officer -
Lloyd Emerson Johnson,
Director -
Stewart W Strong,
President, Global Hospital -
James D Arecca,
EVP, Chief Financial Officer -
Roy Galvin,
President, Global Plasma & BC -
Diane M Bryant,
Director